Select Medical (SEM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
15 Apr, 2026Executive summary
A special meeting will be held for shareholders to vote on a proposed merger where the company will be acquired by a consortium led by senior executives and WCAS XIV, L.P., taking the company private at $16.50 per share, an 18% premium to the unaffected price and 25% over the 90-day average.
The board formed a Special Committee of independent directors to evaluate the transaction, which, after extensive negotiations and outreach to other potential bidders, unanimously recommended the merger as fair and in the best interests of unaffiliated shareholders.
The merger will be financed through a combination of equity from WCAS, debt financing, and rollover equity from management and certain shareholders, with no financing condition to closing.
If approved, the company will be delisted from the NYSE and become a wholly owned subsidiary of the acquirer; shareholders (other than rollover participants) will receive cash, and appraisal rights are available under Delaware law.
Voting matters and shareholder proposals
Shareholders will vote on: (1) the merger agreement, (2) a non-binding advisory vote on executive compensation related to the merger, and (3) a proposal to adjourn the meeting if more time is needed to solicit votes.
Approval of the merger requires a majority of outstanding shares and a majority excluding shares held by the acquirer and affiliates.
Rollover holders and certain executives have agreed to vote their shares in favor of the merger.
Board of directors and corporate governance
The Special Committee, composed solely of independent and disinterested directors, led the negotiation and evaluation process, retained independent legal and financial advisors, and had full authority over the process.
The board cannot approve the merger without a prior favorable recommendation from the Special Committee.
After the merger, the board of the surviving corporation will be composed of the directors of the merger sub, and current officers will continue in their roles.
Latest events from Select Medical
- Merger and compensation proposals approved; official results to be filed on Form 8-K.SEM
AGM 2026 - Special meeting to vote on $16.50/share cash merger, with board and committee unanimous support.SEM
Proxy filing - Special Committee recommends approval of a $16.50/share going-private merger, offering an 18% premium.SEM
Proxy filing - Revenue up 5%, but net income and EBITDA fell; merger expected mid-2026, guidance maintained.SEM
Q1 2026 - Board seeks annual director elections, 25% special meeting threshold, and strong governance.SEM
Proxy Filing - Key votes include board structure changes, executive pay, and special meeting rights.SEM
Proxy Filing - Q3 2025 revenue up 7.2%, EPS up 21%, margins pressured, 2025 outlook reaffirmed.SEM
Q3 2025 - Q2 revenue up 5.1% to $1.76B; Concentra IPO raised $528.8M, reducing debt by $1.9B.SEM
Q2 2024 - Revenue, net income, and liquidity improved, with Concentra IPO and debt reduction as key highlights.SEM
Q3 2024